XNCR
NASDAQ
$18.81
Xencor Inc (XNCR)
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $28.33 (+50.61%)
Market Cap
$1.11B
FCF 5Y CAGR
+29.44%
Free Cash Flow Yield
-17.02%
Beta (5Y)
1.42
Price Chart
Valuation
Market Cap$1.11B
Forward P/E68.03
P/S11.41
P/B2.15
Profitability
Total Revenue (TTM)$97M
Gross Profit (TTM)-$148M
EBITDA-$202M
Profit Margin-177.1%
Operating Margin-1724%
EPS-$2.35
Financial Health
Debt-to-Equity21%
Free Cash Flow Yield-17.02%
Growth & Risk
EPS 5Y CAGR+10.21%
Revenue 5Y CAGR+2.91%
FCF 5Y CAGR+29.44%
Beta (5Y)1.42
Sharpe Ratio1.38